GoAI
Get started
Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$11.88

+$0.18 · +1.54%

Aug 21, 3:55 PM ET

KURA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

88

Deep Value

Momentum

64

Gaining

Sentiment

53

Mixed

Risk resilience

61

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Troy Wilson
Listed since
Sep 16, 2015
Employees
260

Market position

Volume
2.03M
1.18× average
Average volume
1.72M
Average daily volume
Market cap
1.06B USD
Beta
0.38
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
782.31M USD
P/E (TTM)
-3.53×
P/B (TTM)
21.81×
P/S (TTM)
13.67×
EV / EBITDA
-2.84×
Earnings yield
-30.59%
Free cash flow yield
-7.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
94.73%
Operating margin
-411.90%
Net margin
-384.30%
Return on equity
-160.03%
Return on assets
-37.74%
Return on invested capital
-48.76%

Financial health

Debt / equity
0.5×
Current ratio
6.06×
Altman Z-score
-2.59
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends155%-65%-285%-505%Gross margin, FY2024: 100.00%Gross margin, FY2025: 99.92%Operating margin, FY2024: -358.55%Operating margin, FY2025: -449.94%Net margin, FY2024: -322.89%Net margin, FY2025: -412.95%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 99.92%. Operating margin FY2024 -358.55%. Operating margin FY2025 -449.94%. Net margin FY2024 -322.89%. Net margin FY2025 -412.95%.

Income trends

Revenue

67.48M USD+25.24%

Operating income

−303.63M USD-57.16%

Net income

−278.67M USD-60.17%
Income trends across reported periods104.59M USD−43.85M USD−192.3M USD−340.74M USDRevenue, FY2024: 53.88M USDRevenue, FY2025: 67.48M USDOperating income, FY2021: −131.26M USDOperating income, FY2022: −139.87M USDOperating income, FY2023: −165.8M USDOperating income, FY2024: −193.2M USDOperating income, FY2025: −303.63M USDNet income, FY2021: −130.47M USDNet income, FY2022: −135.84M USDNet income, FY2023: −152.63M USDNet income, FY2024: −173.98M USDNet income, FY2025: −278.67M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 53.88M USD. Revenue FY2025 67.48M USD. Operating income FY2021 −131.26M USD. Operating income FY2022 −139.87M USD. Operating income FY2023 −165.8M USD. Operating income FY2024 −193.2M USD. Operating income FY2025 −303.63M USD. Net income FY2021 −130.47M USD. Net income FY2022 −135.84M USD. Net income FY2023 −152.63M USD. Net income FY2024 −173.98M USD. Net income FY2025 −278.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue67.48M USD53.88M USD———
Cost of goods sold57K USD—849K USD——
Gross profit67.43M USD53.88M USD−849K USD——
Research and development251.07M USD169.97M USD115.24M USD92.81M USD84.72M USD
Selling, general, and administrative119.98M USD77.11M USD50.57M USD47.05M USD46.54M USD
Operating expenses371.06M USD247.08M USD164.96M USD139.87M USD131.26M USD
Interest income26.77M USD22.85M USD14.72M USD4.25M USD1.21M USD
Interest expense1.51M USD1.62M USD1.55M USD229K USD414K USD
Depreciation and amortization1.03M USD848K USD849K USD759K USD558K USD
Operating income−303.63M USD−193.2M USD−165.8M USD−139.87M USD−131.26M USD
Net income−278.67M USD−173.98M USD−152.63M USD−135.84M USD−130.47M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-3.18
FY2025
Latest fiscal-year revenue
67.48M USD
FY2025 · +25.24% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-1.85-2.33-2.82-3.3FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend74.23M47.24M20.24M-6.75MFY21FY22FY23FY24FY25

KURA news

zacks.com

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
zacks.com

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising…

Read source
defenseworld.net

Assenagon Asset Management S.A. Trims Holdings in Kura Oncology, Inc. $KURA

Assenagon Asset Management S.A. lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 21.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange…

Read source
seekingalpha.com

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Kura Oncology Q2 Earnings Call Highlights

Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a…

Read source
zacks.com

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.75 per share a year ago.

Read source

KURA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KURA

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
37.8M
Weight
0.33%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
25.56M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
25.22M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
9.37M
Weight
0.06%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.27M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
7.57M
Weight
0.07%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
5.83M
Weight
0.09%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
4.98M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research KURA

research.disclaimer